These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 6202772)

  • 1. Effects of deoxycoformycin in mice. II. Differences between the drug sensitivities and purine metabolizing enzymes of transplantable lymphomas of varying immunologic phenotypes.
    Ratech H; Kim J; Asofsky R; Thorbecke GJ; Hirschhorn R
    J Immunol; 1984 Jun; 132(6):3077-84. PubMed ID: 6202772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific immunosuppressive effects of constant infusion of 2'-deoxycoformycin.
    Trotta PP; Tedde A; Ikehara S; Pahwa R; Good RA; Balis ME
    Cancer Res; 1981 Jun; 41(6):2189-96. PubMed ID: 6972248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of 2'-deoxycoformycin on the metabolism of purines and the survival of malignant cells in a patient with T-cell leukemia.
    Yu AL; Bakay B; Kung FH; Nyhan WL
    Cancer Res; 1981 Jul; 41(7):2677-82. PubMed ID: 6972800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity and immunosuppressive activity of binary combinations of 2'-deoxycoformycin and 2'-deoxyadenosine.
    Paine RM; Weston BJ; Clink HM; Kohn J; Neville AM; McGhee KG; Harrap KR
    Cancer Treat Rep; 1981; 65(3-4):259-66. PubMed ID: 6972254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2'Deoxycoformycin and deoxyadenosine affect IL 2 production and IL 2 receptor expression of human T cells.
    Ruers TJ; Buurman WA; van der Linden CJ
    J Immunol; 1987 Jan; 138(1):116-22. PubMed ID: 3097141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specificity of 2'-deoxycoformycin inhibition of adenosine metabolism in intact human skin fibroblasts.
    Holland MJ
    Res Commun Chem Pathol Pharmacol; 1986 Mar; 51(3):311-24. PubMed ID: 3486439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphologic changes and immunohistochemical localization of adenosine deaminase in tissues of rats given injections of 2'-deoxycoformycin.
    Checkik BE; Perets A; SenGupta S; Fernandes B
    J Natl Cancer Inst; 1983 Nov; 71(5):999-1010. PubMed ID: 6358608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of deoxycoformycin in mice. III. A murine model reproducing multi-system pathology of human adenosine deaminase deficiency.
    Ratech H; Hirschhorn R; Thorbecke GJ
    Am J Pathol; 1985 Apr; 119(1):65-72. PubMed ID: 3872599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of deoxycoformycin in mice. I. Suppression and enhancement of in vivo antibody responses to thymus-dependent and -independent antigens.
    Ratech H; Bell MK; Hirschhorn R; Thorbecke GJ
    J Immunol; 1984 Jun; 132(6):3071-6. PubMed ID: 6609968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opposite effects of recombinant interferon-alpha A and deoxycoformycin on adenosine deaminase activity in the Daudi B lymphoblastoid cell line.
    Faltynek CR
    Blood; 1988 Jan; 71(1):59-64. PubMed ID: 3257147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human B lymphocytes and thymocytes but not peripheral blood mononuclear cells accumulate high dATP levels in conditions simulating ADA deficiency.
    Goday A; Simmonds HA; Morris GS; Fairbanks LD
    Biochem Pharmacol; 1985 Oct; 34(19):3561-9. PubMed ID: 3876835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of adenosine deaminase activity in cultured murine cytotoxic T lymphocytes.
    Minkowski MD; Castellazzi M; Buttin G
    J Immunol; 1984 Jul; 133(1):52-8. PubMed ID: 6609994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of deoxyadenosine on the activation of ADA inhibited T & B cells.
    Webster AD; Ip H; Pereira S
    Clin Exp Immunol; 1982 Dec; 50(3):587-95. PubMed ID: 6299634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme activities of leukemic cells and biochemical changes induced by deoxycoformycin in vitro--lack of correlation with clinical response.
    Ho AD; Ganeshaguru K; Knauf W; Dietz G; Trede I; Hoffbrand AV; Hunstein W
    Leuk Res; 1989; 13(4):269-78. PubMed ID: 2785618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of growth-inhibitory activity of 9-beta-D-arabinofuranosyladenine by 2'-deoxycoformycin in human cultured cell lines derived from leukemias and lymphomas.
    Kuroki Y; Shimoyama M; Inaba S; Hirose M
    Jpn J Cancer Res; 1989 May; 80(5):482-9. PubMed ID: 2502523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation of deoxycoformycin-resistant cells with increased levels of adenosine deaminase.
    Hoffee PA; Hunt SW; Chiang J
    Somatic Cell Genet; 1982 Jul; 8(4):465-77. PubMed ID: 6981855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2'-Deoxycoformycin inhibition of adenosine deaminase in rat brain: in vivo and in vitro analysis of specificity, potency, and enzyme recovery.
    Padua R; Geiger JD; Dambock S; Nagy JI
    J Neurochem; 1990 Apr; 54(4):1169-78. PubMed ID: 2179470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Animal model for immune dysfunction associated with adenosine deaminase deficiency.
    Tedde A; Balis ME; Ikehara S; Pahwa R; Good RA; Trotta PP
    Proc Natl Acad Sci U S A; 1980 Aug; 77(8):4899-903. PubMed ID: 6968908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic abnormalities of human adenosine deaminase deficiency reproduced in the mouse by 2'-deoxycoformycin, and adenosine deaminase inhibitor.
    Ratech H; Thorbecke GJ; Hirschhorn R
    Clin Immunol Immunopathol; 1981 Oct; 21(1):119-27. PubMed ID: 6268339
    [No Abstract]   [Full Text] [Related]  

  • 20. Mechanisms of deoxyadenosine toxicity in human lymphoid cells in vitro: relevance to the therapeutic use of inhibitors of adenosine deaminase.
    Lee N; Russell N; Ganeshaguru K; Jackson BF; Piga A; Prentice HG; Foa R; Hoffbrand AV
    Br J Haematol; 1984 Jan; 56(1):107-19. PubMed ID: 6231047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.